NYSE$TFX
Teleflex Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Teleflex reported an increase in revenue and adjusted EPS, driven by solid revenue growth and improved margins, despite challenges from COVID-19 and a respiratory divestiture.
Teleflex reported strong second-quarter results with a 25.8% increase in revenue to $713.5 million and adjusted EPS of $3.35, up 73.6% year-over-year. The company is maintaining its constant currency revenue guidance and raising its full-year adjusted earnings per share guidance, despite dilution from the respiratory asset sale.
- Reported revenues increased by 25.8% year-over-year, reaching $713.5 million.
- GAAP diluted EPS from continuing operations was $1.76, compared to $0.24 in the prior year period.
- Adjusted diluted EPS from continuing operations rose to $3.35, a 73.6% increase year-over-year.
- The company divested the majority of its respiratory assets on June 28, 2021.
Headline financials
Revenue & EPS history
Teleflex · Revenue · Quarterly
$713M
Revenue by segment
Teleflex · $415M total across 1 segment · Q2 2021
- Americas Segment$415M+32.7%100.0%
Forward guidance
Teleflex maintained its 2021 GAAP revenue growth guidance of 10.50% to 11.75% year-over-year and raised its 2021 GAAP diluted earnings per share from continuing operations to a range of $9.50 to $9.60. The company raised its 2021 adjusted diluted earnings per share from continuing operations to a range of $12.90 to $13.10.
Tailwinds
- Maintaining 2021 GAAP revenue growth guidance of 10.50% to 11.75% year-over-year.
- Reaffirming 2021 revenue growth guidance of at least 30% year-over-year for the Interventional Urology business.
- Raising 2021 GAAP diluted earnings per share from continuing operations to a range of $9.50 to $9.60.
- Raising 2021 adjusted diluted earnings per share from continuing operations to a range of $12.90 to $13.10.
- Maintaining 2021 constant currency revenue growth guidance range of 8.50% to 9.75% year-over year.
Headwinds
- Includes a $28 to $32 million headwind in the second half of 2021 from the respiratory divestiture.
- GAAP and adjusted earnings per share reflect $0.10 to $0.15 dilution in the second half of 2021 from the respiratory divestiture.
- Unspecified impact of COVID-19 on product lines and geographic segments.
- Potential changes in business relationships with major customers or suppliers.
- Possible delays or cancellations in shipments.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-0.4%
Avg return
Earnings day
-2.6%
Avg return
5 days after
-1.9%
Avg return
30 days after
53%
36 / 68 earnings
Positive
+12.5%
Q3 2023
Best reaction
-21.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.9% | +4.6% | +5.2% | |
| Q4 2025 | +6.5% | +9.2% | +3.9% | |
| Q3 2025 | -13.3% | -10.0% | -3.4% | |
| Q1 2025 | -8.2% | -12.0% | -10.8% | |
| Q4 2024 | -21.7% | -26.4% | -22.4% | |
| Q3 2024 | -10.2% | -13.5% | -18.0% | |
| Q2 2024 | +7.3% | +4.5% | +11.0% | |
| Q1 2024 | -4.0% | -4.7% | -1.2% | |
| Q4 2023 | -5.3% | -9.9% | -12.0% | |
| Q3 2023 | +12.5% | +9.2% | +21.4% | |
| Q2 2023 | -4.3% | -7.6% | -14.1% | |
| Q1 2023 | -5.2% | -7.4% | -13.1% | |
| Q4 2022 | -2.3% | -1.0% | +3.4% | |
| Q3 2022 | +3.1% | +5.6% | +8.6% | |
| Q2 2022 | -9.8% | -5.9% | -15.9% | |
| Q1 2022 | -9.7% | -9.9% | -8.3% | |
| Q4 2021 | +6.4% | +3.4% | +5.3% | |
| Q3 2021 | -2.5% | +0.9% | -16.7% | |
| Q2 2021 | -0.5% | -3.6% | -2.8% | |
| Q1 2021 | -4.8% | -7.0% | -9.4% | |
| Q4 2020 | -0.6% | +0.8% | +3.2% | |
| Q3 2020 | -5.0% | -0.8% | +10.8% | |
| Q2 2020 | -7.0% | -8.2% | -4.0% | |
| Q1 2020 | -6.7% | -3.5% | +2.8% | |
| Q4 2019 | -6.3% | -11.9% | -38.3% | |
| Q3 2019 | +4.9% | +1.9% | +7.1% | |
| Q2 2019 | +6.4% | +6.8% | +7.1% | |
| Q1 2019 | +7.0% | +4.9% | +2.7% | |
| Q4 2018 | -0.4% | +0.7% | +5.3% | |
| Q3 2018 | +6.4% | +6.9% | +14.4% | |
| Q2 2018 | -9.2% | -12.4% | -8.6% | |
| Q1 2018 | +0.6% | -0.7% | -0.2% | |
| Q4 2017 | -5.5% | -6.0% | -6.3% | |
| Q3 2017 | +6.1% | +7.7% | +9.9% | |
| Q2 2017 | +5.5% | +4.9% | +3.7% | |
| Q1 2017 | -4.4% | -7.2% | -1.2% | |
| Q4 2016 | +3.1% | +3.9% | +5.9% | |
| Q3 2016 | -9.7% | -11.2% | -2.7% | |
| Q2 2016 | +3.2% | +3.0% | +4.4% | |
| Q1 2016 | -2.8% | — | — | |
| Q4 2015 | +9.6% | — | — | |
| Q3 2015 | +2.4% | — | — | |
| Q2 2015 | -4.5% | — | — | |
| Q1 2015 | +0.6% | — | — | |
| Q4 2014 | +4.6% | — | — | |
| Q3 2014 | +0.7% | — | — | |
| Q2 2014 | +1.9% | — | — | |
| Q1 2014 | +1.6% | — | — | |
| Q4 2013 | +3.0% | — | — | |
| Q3 2013 | +5.5% | — | — | |
| Q2 2013 | +0.2% | — | — | |
| Q1 2013 | -5.9% | — | — | |
| Q4 2010 | -0.4% | — | — | |
| Q4 2012 | +1.0% | — | — | |
| Q3 2012 | +3.7% | — | — | |
| Q2 2012 | +4.4% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q4 2011 | +0.9% | — | — | |
| Q3 2011 | -1.2% | — | — | |
| Q2 2011 | +0.9% | — | — | |
| Q1 2010 | +2.9% | — | — | |
| Q1 2011 | +0.7% | — | — | |
| Q4 2008 | -2.6% | — | — | |
| Q3 2009 | -3.4% | — | — | |
| Q3 2010 | -3.4% | — | — | |
| Q2 2009 | +7.3% | — | — | |
| Q4 2009 | +7.3% | — | — | |
| Q2 2010 | +7.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro